1 / 14

The pathway from basic research to practices and policies

The pathway from basic research to practices and policies. Tim Grant and Gloria Crispino-O’Connell 11 th February 2011 - HSE. CSTAR - Who we are. Founded by a group of academics and health researchers, CSTAR is a partnership of 4 universities, UCD, TCD, NUIG and UL.

rafal
Download Presentation

The pathway from basic research to practices and policies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The pathway from basic research to practices and policies Tim Grant and Gloria Crispino-O’Connell 11th February 2011 - HSE

  2. CSTAR - Who we are • Founded by a group of academics and health researchers, CSTAR is a partnership of 4 universities, UCD, TCD, NUIG and UL. • Supported by the HRB, opened for business on 1st September 2009. It is led by Prof. Leslie Daly, UCD. • Board of Directors and International Advisory Group . • 1 Director, 3 Biostatisticians and 1.5 Administrator

  3. CSTAR - What we do • Provide biostatistical and methodological support to health research studies, both quantitative and qualitative. • Areas of support include: • Study design • Methodological Section of grant applications • Statistical Analysis • Interpretation of results for publication

  4. The translational Continuum Source: Canadian Institute of Public Health The inability to overcome the death valleys is due to multiple factors, including the lack of methodological support.

  5. The context of health research • Development/evaluation of : • Drugs • Medical Devices • Diagnostics tests • Therapy protocols • Health Services Practices • Health status • What is Clinical Research? • Study of drugs, devices, diagnostics and therapies in human subjects with the intent to discover potential beneficial effects and/or determine its safety and efficacy. • Who does it involve? • Collaboration of many personnel with a variety of skills e.g.; medics, scientists, statisticians, nurses, data managers, pharmacists etc.

  6. Drug Development 1 In 10,000 Succeed (to market/practice) Average Time: 10-18Years Average Cost: €500 Million to €2 billion (<20% of sales) 100,000 Examined by FDA and similar bodies (Preclinical Evaluation) 100 Tested in Humans 10 Marketed Drugs 2Drugs Return a Profit

  7. Biomarkers Development Source: MMI – The Irish Biomarker Network Inaugural Workshop

  8. In all application forms… • ..describe clearly all stages of the study design - rationale for sampling strategy, justification of sample size and power calculation, full details on the design chosen to evaluate an intervention, methods of data collection, measures and techniques of analysisfor quantitative and qualitative designs. Source: HRB Health Research Award 2010

  9. Preparation and Perspiration! • A well thought out study should have the following methodological documents completed before recruitment/data collection starts: • Study/Research Protocol • Data Management Plan • Statistical Analysis Plan • Study Report Plan

  10. Design: Research question(s) • Primary and secondary objectives • Generic • Primary and secondary questions • Specific • Primary and secondary variables • More specific (parameters, measurements, data) • Primary and secondary analysis • Nail it!

  11. Statistical Analysis… is the easy part! • Estimation • Confidence Intervals • Hypothesis Testing • Assumption Testing

  12. Cost/Benefit and Effectiveness • A great obstacle to a better health system (drugs, therapies, services etc.) is the difficulty in estimating the costs and benefitsof any intervention. • A cost and benefit study start with a research question! • Fundamental conceptual assumptions: • What do we include as costs and benefits? • ‘How far’ do we measure the impact of an intervention? i.e. Direct and indirect benefits • What methodology do we use to quantify them? • Who should take the burden of such costs? The government, the industry or the patient?

  13. Direct and Indirect Benefits and Costs Monetary value of key parameters: • Life • Better quality of life and loss of life • Prevention of late stage of disease vs the cost of implementing a new therapy • Impact on families, children.. • Social costs Methodologies are driven by policies and practices. Many examples in the literature: Sir Nicholas Stern (UK) 2006, OrleyAshenfelter (Princeton) and Michael Greenstone (Chicago) 2002.

More Related